CoreRx Inc. has completed its previously announced $130 million acquisition of Societal CDMO Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics.
 
As a result of the merger, Societal CDMO is now a wholly-owned subsidiary of CoreRx.
 
According to David Enloe, CEO of Societal CDMO, the enhanced CDMO created through this transaction will be positioned to offer both existing and new customers strength in formulation development, early-stage production, clinical trial services, commercial-scale manufacturing, and a range of packaging services.
 
“The prospects for this combined entity to establish itself as a preferred CDMO partner in the small molecule space are bright and we look forward to the opportunity to contribute to the new company’s success,” Enloe added.

Other Pharma Industry Acquisitions